EudraCT number

ClinicalTrials.gov number

Protocol/serial number

Study information

Scientific title

Acronym

Study hypothesis

Coronary artery disease (CAD) is a leading cause of death and disability worldwide. Around 20-40% of the UK population will experience chest pain during their lifetime, accounting for 40% of acute hospital admissions. Oxygen has long been advocated as a therapeutic agent and treatment option in the management of chest pain, although the scientific basis for this is questionable and there is currently no clinical evidence to support the routine use of oxygen in the setting of myocardial ischaemia. Experimental data suggests hyperoxaemia may actually be harmful purported to be due to alteration in microvascular function. This study is divided into two parts: A. we intend to quantify myocardial blood flow with cardiovascular magnetic resonance (CMR) scanning. B. we intend to use novel invasive coronary physiological measurements to assess the dynamic response of the coronary microvasculature to the hyperoxaemic stimulation. This study will establish the implications of high flow oxygen on coronary microvascular function and may have a direct impact on clinical care and the management of patients presenting with chest pain.

Ethics approval

14/YH/1089

Study design

Non-randomised; Interventional; Design type: Treatment

Primary study design

Interventional

Secondary study design

Non randomised study

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet